Drug Therapy

Alastair J. J. Wood, M.D., Editor

CALCIUM-ANTAGONIST DRUGS
Darrell R. Abernethy, M.D., Ph.D., and Janice B. Schwartz, M.D.

DRUGS classified as calcium antagonists or calcium-channel blockers were introduced into clinical medicine in the 1960s and are now among the most frequently prescribed drugs for the treatment of cardiovascular diseases. Although the currently available calcium antagonists are chemically diverse, they share the common property of blocking the transmembrane flow of calcium ions through voltage-gated L-type (slowly inactivating) channels. These drugs have proved effective in patients with hypertension, angina pectoris, and cardiac arrhythmias and may be beneficial in patients with left ventricular diastolic dysfunction, Raynaud’s phenomenon, migraine, preterm labor, esophageal spasm, and bipolar disorders.

L-TYPE CALCIUM CHANNELS

All calcium antagonists bind to the \( \alpha_1 \) subunit of the L-type calcium channel (Fig. 1), which is the main pore-forming unit of the channel. This subunit is associated with a disulfide-linked \( \alpha_\text{II} \delta \) subunit and an intracellular \( \beta \) subunit. The \( \alpha_\text{II} \delta \) and \( \beta \) subunits modulate the \( \alpha_1 \) subunit. The phenylalkylamine (verapamil-like) calcium antagonists bind to transmembrane segment 6 of motif IV (IVS6), the benzothiazepine (diltiazem-like) calcium antagonists bind to the cytoplasmic bridge between motif III (IIIS) and motif IV (IVS), and the dihydropyridine (nifedipine-like) calcium antagonists bind to transmembrane segment 6 of both motif III (IIIS6) and motif IV (IVS6) (Fig. 1).

The L-type calcium channel was first isolated from cardiac muscle and has since been found in vascular smooth muscle (arteriolar and venous), nonvascular smooth muscle (bronchial, gastrointestinal, genitourinary, and uterine), and noncontractile tissues (pancreas, pituitary, adrenal glands, salivary glands, gastric mucosa, white cells, platelets, and lacrimal tissue). Blockade of L-type channels in vascular tissues results in the relaxation of vascular smooth muscle and in cardiac tissue results in a negative inotropic effect. The ability of these drugs to decrease smooth-muscle and myocardial contractility results in both clinically desirable antihypertensive and antianginal effects and undesirable myocardial depression.

Other calcium channels with electrophysiologic properties have also been identified. These channels, to which the calcium antagonists do not bind, include the N-type channels in neuronal tissue, P-type channels in Purkinje tissues, and T-type (transient potential) channels in cardiac nodal structures and vascular smooth muscle.

Regulation of the L-type channels may differ in different types of cells. In cardiac myocytes, these channels are activated by catecholamines and other stimuli that activate adenylyl cyclase or cyclic adenosine monophosphate-dependent protein kinase. In contrast, these stimuli activate, inhibit, or have no effect on L-type calcium channels in vascular and visceral smooth-muscle beds, depending on the experimental conditions. L-type channels are also activated by the \( \alpha_1 \)-adrenergic system, angiotensin II, and endothelin. As an in vivo correlate of these findings, calcium antagonists block the responses of vascular smooth muscle to phenylephrine, angiotensin II, and endothelin-1 in humans. In addition to hormonal activation by means of signal-transduction pathways, L-type channels may be directly activated at the plasma membrane by guanine nucleotide-binding (G) proteins produced in response to hormone binding to its receptors.

CALCIUM CHANNELS AND CELL GROWTH

L-type (and T-type) calcium channels seem to have a role in cellular growth and proliferation in addition to their role in the acute changes in ion flux associated with changes in membrane potential. Several calcium antagonists, and possibly all, can inhibit the growth and proliferation of vascular smooth muscle and fibroblasts. All classes of calcium antagonists decrease the growth of vascular smooth-muscle cells in vitro and in animals, as measured by decreased uptake of uridine (RNA synthesis) and incorporation of leucine (protein synthesis) at drug concentrations associated with clinical effects. Calcium antagonists may also inhibit the synthesis of extracellular-
matrix collagen proteins, and they prevent atherosclerosis in animals with hyperlipidemia. However, in most clinical studies calcium antagonists did not reverse or slow the progression of atherosclerosis.

CLINICAL PHARMACOLOGY

Nine calcium antagonists are currently marketed in the United States for the treatment of hypertension, angina, and supraventricular arrhythmias, and one — nimodipine — is approved for short-term use in patients with subarachnoid hemorrhage (Table 1). Only diltiazem, nicardipine, and verapamil are available in intravenous formulations, and long-term treatment with calcium antagonists is usually by the oral route.

Pharmacokinetics

After oral administration, the bioavailability of these drugs varies depending on first-pass metabolism in the intestinal wall and liver. All are metabolized to less active metabolites in the liver by oxidative pathways, predominantly by cytochrome P-450 CYP3A, a subgroup of the cytochrome P-450 enzyme family, and to a lesser extent by other members of this enzyme family. All calcium antagonists, with the exception of diltiazem and nifedipine, are administered as racemic mixtures, with one active and one inactive stereoisomer with respect to blockade of L-type calcium channels. The cytochrome P-450 CYP3A enzymes metabolize each isomer at a different rate, resulting in stereoselective drug clearance. Hepatic biotransformation of calcium antagonists such as verapamil may be greater in women than men.

Pharmacodynamics

All currently available calcium antagonists cause vasodilation, with lowering of blood pressure. Their rel-
ative potency as vasodilators varies, with nifedipine typically considered the most potent of the dihydropyridines, and verapamil, diltiazem, and bepridil having less potency. In vitro, several calcium antagonists (e.g., nifedipine, nisoldipine, and isradipine) bind with some selectivity to the L-type calcium channel in blood vessels, whereas verapamil binds equally well to cardiac and vascular L-type calcium channels.\textsuperscript{29,30} The relevance of these in vitro findings to treatment in humans is not known. In vitro, all classes of calcium-channel blockers depress sinus-node activity and slow atrioventricular conduction, yet only verapamil and diltiazem delay atrioventricular conduction or cause sinus-node depression at doses used clinically. Similarly, all classes cause concentration-dependent decreases in myocardial contractility in vitro, but only verapamil and diltiazem do so in vivo. The disparities between the in vitro and in vivo effects are probably explained by the sympathetic activation that occurs in response to the vasodilation induced by dihydropyridines, which blunts their direct negative chronotropic and inotropic effects.

### THERAPEUTIC USES AND CONTROVERSIES

#### Hypertension

In the United States, amlodipine, diltiazem, felodipine, isradipine, nicardipine, nifedipine, nisoldipine, and verapamil are currently approved for the treatment of patients with hypertension (Table 1). Each of these drugs lowers diastolic blood pressure during long-term oral administration at the recommended doses. Most are available in long-acting formulations that permit once-daily administration. In the United States, calcium antagonists are currently recommended as first-line therapy for hypertension only if there is a compelling reason not to administer a thiazide diuretic or a beta-blocker.\textsuperscript{31} This recommendation is based on the lack of evidence that treatment with calcium antagonists reduces hypertension-related morbidity and mortality. A reported exception is the decrease in stroke with the use of nitrendipine for the treatment of systolic hypertension in the elderly in the Systolic Hypertension in Europe Trial.\textsuperscript{32} However, nitrendipine is not available in the United States.

### TABLE 1. CLINICAL DOSING INFORMATION FOR THE CALCIUM ANTAGONISTS APPROVED FOR USE IN THE UNITED STATES.

<table>
<thead>
<tr>
<th>DRUG</th>
<th>APPROVED INDICATIONS</th>
<th>FORM AND DOSE</th>
<th>TIME TO PEAK EFFECT</th>
<th>ELIMINATION HALF-LIFE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amlodipine</td>
<td>Angina, hypertension</td>
<td>Tablet; 2.5–10 mg once daily</td>
<td>6–12</td>
<td>30–50</td>
</tr>
<tr>
<td>Bepridil*</td>
<td>Refractory angina</td>
<td>Tablet; 200–400 mg once daily</td>
<td>2–3</td>
<td>26–64</td>
</tr>
<tr>
<td>Diltiazem†</td>
<td>Angina, hypertension</td>
<td>Immediate-release tablet; dose varies depending on indication Sustained-release tablet; 180–480 mg once daily</td>
<td>0.5–1.5</td>
<td>2–5</td>
</tr>
<tr>
<td>Isradipine</td>
<td>Hypertension</td>
<td>Sustained-release tablet; 2.5–10 mg once daily</td>
<td>2.5–5</td>
<td>11–16</td>
</tr>
<tr>
<td>Nicardipine†</td>
<td>Angina, hypertension</td>
<td>Immediate-release tablet; 20–40 mg three times daily</td>
<td>0.5–2.0</td>
<td>8</td>
</tr>
<tr>
<td>Nifedipine</td>
<td>Angina, hypertension</td>
<td>Immediate-release capsule; dose varies depending on indication Sustained-release capsule; 30–120 mg once daily</td>
<td>0.5</td>
<td>2</td>
</tr>
<tr>
<td>Nimodipine</td>
<td>Subarachnoid hemorrhage</td>
<td>Capsule; 60 mg every 4 hr for 21 days</td>
<td>1</td>
<td>1–2</td>
</tr>
<tr>
<td>Nisoldipine</td>
<td>Angina, hypertension</td>
<td>Sustained-release tablet; 20–40 mg once daily</td>
<td>6–12</td>
<td>7–12</td>
</tr>
<tr>
<td>Verapamil†</td>
<td>Angina, hypertension</td>
<td>Immediate-release tablet; dose varies depending on indication Sustained-release tablet; 120–480 mg once daily</td>
<td>0.5–1.0</td>
<td>4.5–12</td>
</tr>
</tbody>
</table>

---

* Bepridil is indicated only for patients with angina that is refractory to treatment with other drugs.
† This drug is also available in an intravenous formulation, with a time to peak effect ranging from 5 to 18 minutes after administration.
Several retrospective case–control studies have suggested that treatment of hypertension with primarily short-acting calcium antagonists may be associated with an increased incidence of myocardial infarction. These data have been unconvincing to many.

Concomitant with these reports, the prospective, randomized Multicenter Isradipine Diuretic Atherosclerosis Study, which was designed to compare the rates of progression of carotid atherosclerosis in patients treated with hydrochlorothiazide and those given isradipine, demonstrated, as a secondary finding, that the isradipine-treated patients had an increased incidence of both angina pectoris and a composite group of vascular events. However, the data suggesting an association between calcium-antagonist therapy and myocardial infarction in patients with hypertension cannot be considered conclusive. A potential mechanism for these outcomes, if they are real, may be reflex sympathetic stimulation of β-adrenergic receptors. Sympathetic stimulation occurs after rapid intravenous administration of verapamil, diltiazem, or nifedipine or oral administration of short-acting dihydropyridines in normal subjects and patients with hypertension. Less well recognized is the evidence of sympathetic stimulation during the administration of sustained-release nifedipine.

Patients with diabetes mellitus may represent a special subgroup for whom calcium-antagonist therapy increases the risk of cardiovascular complications. Further analysis of the data from the Multicenter Isradipine Diuretic Atherosclerosis Study indicated that the adverse effects of isradipine occurred in patients with high glycosylated hemoglobin values, suggesting that there is a relation between glucose intolerance and an increased risk of vascular events. Another prospective comparison of enalapril and nisoldipine in patients who had hypertension and type 2 diabetes revealed a higher incidence of myocardial infarction among the patients who received nisoldipine. Similarly, in the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial, a prospective comparison of fosinopril and amlodipine in hypertensive patients of all ages who had type 2 diabetes, the overall rate of cardiovascular events was higher among the patients who received amlodipine. The results of these studies weaken arguments that the adverse outcomes associated with calcium antagonists are limited to the rapid-acting and the short-acting drugs, because both sustained-release nisoldipine and isradipine — with an elimination half-life of 8 to 12 hours — have been associated with similar adverse outcomes.

In contrast, retrospective analyses of the relative benefits of antihypertensive-drug therapy in elderly patients who had systolic hypertension with or without diabetes found that twice-daily nitrrendipine had greater cardiovascular benefit in patients with diabetes than in those without diabetes. The results of this trial are insufficient to permit conclusions to be drawn regarding the relative benefit of nitrrendipine alone as compared with nitrrendipine in combination with other types of antihypertensive therapy (angiotensin-converting–enzyme inhibitors or diuretics). Nitrrendipine is currently not approved for marketing in the United States. For U.S. practitioners, the available data do not support a recommendation that a calcium antagonist should be the first choice for patients who have hypertension and diabetes.

Angina Pectoris

Calcium antagonists are effective in the treatment of both classic angina pectoris and the less frequent vasospastic, or variant, angina (Prinzmetal’s angina). In the United States, amlodipine, diltiazem, nicardipine, nifedipine, and verapamil are approved for the treatment of angina (Table 1). In addition, bepridil is indicated only for patients with angina that is refractory to treatment with other drugs. With the exception of the rapid-acting formulations, which may occasionally worsen angina, each of these drugs substantially prolongs the time to the onset of angina during exercise, decreases the frequency of episodes of angina, or decreases the need for short-acting nitroglycerin in patients who require long-term oral administration of nitroglycerin. Although calcium antagonists are effective as monotherapy for angina, combined treatment with a calcium antagonist, a nitrate, and a beta-blocker can have an additive effect. Particularly effective combinations for patients with stable angina include either a dihydropyridine and a beta-blocker or verapamil or diltiazem in combination with a nitrate, followed by the addition of a beta-blocker in patients with unsatisfactory control of angina. Calcium-antagonist therapy alone is not effective in patients with unstable angina.

The comparative effects on morbidity or mortality of long-term therapy with various calcium antagonists in patients with stable angina are not known. A retrospective review of data has led to concern that the risk of death may be slightly higher among patients who receive dihydropyridine calcium antagonists.

Supraventricular Arrhythmias

Verapamil and diltiazem are approved for the treatment of patients with supraventricular arrhythmias — specifically for the short- and long-term treatment of atrial fibrillation, atrial flutter, and atrioventricular nodal reentry in patients without accessory bypass tracts (Table 1). Verapamil and diltiazem slow conduction through the atrioventricular node and increase the atrioventricular nodal refractory period, which, in turn, results in the slowing of the ventricular response rate in atrial fibrillation or flutter or in the conversion of atrioventricular nodal reentry tachyarrhythmias to sinus rhythm by disruption of the tim-
ing of the reentry circuit. As with the other effects of verapamil on the blockade of L-type calcium channels, this is a stereospecific effect, with S-verapamil causing a delay in atrioventricular nodal conduction and R-verapamil having little effect.26-28 The ability of verapamil and diltiazem to block the actions of the atrioventricular node is more pronounced at faster than slower heart rates, a property termed “use dependency” or “frequency dependency.” Verapamil and diltiazem may also cause sinus-node depression. At clinically tolerated doses, dihydropyridine calcium antagonists do not prolong atrioventricular conduction or refractoriness or cause sinus-node depression and therefore are not indicated for the treatment of supraventricular arrhythmias. The different electrophysiologic effects may be due to differing effects on voltage and use dependency between phenylalkylamine and benzothiazepine drugs, on the one hand, as compared with the dihydropyridine drugs, on the other. Alternatively, the differences may be related to differences among the various classes of drugs in their action on T-type calcium channels, which are more prominent in cardiac nodal structures.

Long-term administration of verapamil or diltiazem slows the ventricular response rate and increases exercise tolerance in patients with chronic atrial fibrillation.52 However, neither drug prevents atrial fibrillation or flutter or completely suppresses episodes of atrioventricular nodal reentry arrhythmia, whether given alone or in combination with digoxin or a beta-blocker. Ongoing trials are evaluating the relative efficacy of controlling the ventricular rate as compared with maintaining sinus rhythm in patients with chronic atrial fibrillation. The results should further elucidate the role of treatment with verapamil and diltiazem.53,54

Subarachnoid Hemorrhage

Nimodipine is approved for the treatment of patients who have had subarachnoid hemorrhage, but its usefulness in clinical practice is uncertain. In animals with regional brain ischemia, nimodipine increased regional blood flow and led to a decrease in blood flow in brain tissue.55 In patients with subarachnoid hemorrhage, the administration of nimodipine resulted in slightly better recovery of function than did placebo.56 Neither nimodipine nor other calcium antagonists were beneficial in patients with ischemic stroke.57

Myocardial Infarction

In vitro studies and experiments in animals have suggested that treatment with calcium antagonists could limit the size of myocardial infarcts or preserve myocardium after ischemia.58 Their benefit in patients who have had a myocardial infarction is limited. In a large, randomized study of patients who had a nontransmural myocardial infarction, mortality was similar in the diltiazem and placebo groups.59 In post hoc analyses, the mortality rate was slightly higher among patients with decreased left ventricular function who received diltiazem and slightly lower among patients with normal left ventricular function who received it. More recently, a trend toward a higher rate of cardiac events was reported among patients who were treated with short-acting nifedipine or diltiazem after a myocardial infarction.60 In contrast, in a large, randomized, placebo-controlled trial of verapamil in patients with myocardial infarction, long-term mortality was lower in the verapamil group,61 and a retrospective analysis of the results suggested that the benefit was greatest in patients without congestive heart failure.62 A smaller randomized, placebo-controlled study found that verapamil had no effect on the risk of death but significantly lowered the rates of reinfarction.63 Trials of longer-acting calcium antagonists found either no adverse effects64 or beneficial effects.65 These studies predated the current therapeutic guidelines for patients with a recent myocardial infarction, which call for the administration of a beta-blocker and aspirin, with or without an angiotensin-converting—enzyme inhibitor.66 It is therefore difficult to place in perspective the data comparing calcium antagonists with placebo in patients with myocardial infarction. There is agreement that short-acting calcium antagonists are contraindicated, and the available data do not support the routine use of a longer-acting calcium antagonist. However, treatment with verapamil may be appropriate for patients who have contraindications to treatment with beta-blockers.66

Risk of Cancer

A retrospective study of older patients with a new diagnosis of cancer suggested that patients who were taking a calcium antagonist had a higher risk of cancer than those who were taking a beta-blocker or an angiotensin-converting—enzyme inhibitor.67 A series of population-based studies followed, data from the Cardiovascular Health Study suggested that the risk of breast cancer was increased in women who were taking a calcium antagonist.68 In contrast, studies from Denmark69 and Scotland70 and another retrospective study from the United States71 concluded that calcium-antagonist therapy did not increase the risk of any type of cancer among patients with hypertension.

DRUG INTERACTIONS

Pharmacokinetic Basis

The CYP3A group of cytochrome P-450 isoenzymes has a major role in the oxidative biotransformation of all the calcium antagonists.23-25 In addition, verapamil inhibits P-glycoprotein—mediated drug transport, which may alter the intestinal absorption of several drugs and their distribution into peripheral tissues and the central nervous system.72,73

Reported and possible drug, dietary, and other
types of interactions with calcium antagonists and the underlying mechanism (if known) are shown in Tables 2 and 3. In general, verapamil and diltiazem inhibit the clearance of other substrates of cytochrome P-450 CYP3A (e.g., carbamazepine, cyclosporine, lovastatin, simvastatin, midazolam, triazolam, terfenadine, and astemizole), whereas the dihydropyridine drugs do not. Verapamil and diltiazem can also increase the absorption of drugs such as cyclosporine that are substrates for P-glycoprotein-mediated drug transport.73,74 This interaction has been exploited clinically by using verapamil or diltiazem to treat hypertension in cyclosporine-treated patients, thus allowing a reduction in the dose of cyclosporine. In vitro data suggest that dihydropyridines are not transported by and do not inhibit P-glycoprotein. Inducers and inhibitors of cytochrome P-450 CYP3A-mediated biotransformation of drugs, however, can affect the metabolism of dihydropyridines as well as verapamil and diltiazem. For example, during treatment with dihydropyridines, the ingestion of large amounts of grapefruit juice may increase the bioavailability of these drugs,75 but the clinical importance of this interaction is uncertain.76

**Interactions with Cardiac Glycosides**

Verapamil consistently increases serum digoxin concentrations by decreasing the clearance and volume of distribution of the drug, but diltiazem and dihydropyridines do not have this effect.77,78 The mechanism of this interaction is probably due in part to verapamil-induced inhibition of P-glycoprotein-mediated transport of digoxin into peripheral tissues.73 Verapamil also decreases the clearance of digitoxin.28 After verapamil

<table>
<thead>
<tr>
<th>TABLE 2. REPORTED OR POSSIBLE INHIBITORY EFFECTS OF CALCIUM ANTAGONISTS ON OTHER DRUGS.*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CALCIUM ANTAGONIST AND</strong></td>
</tr>
<tr>
<td><strong>Bepridil</strong></td>
</tr>
<tr>
<td><strong>Verapamil</strong></td>
</tr>
<tr>
<td><strong>Diltiazem, verapamil</strong></td>
</tr>
<tr>
<td><strong>Antihistamines</strong></td>
</tr>
<tr>
<td><strong>Terfenadine</strong></td>
</tr>
<tr>
<td><strong>Cisapride</strong></td>
</tr>
<tr>
<td><strong>Quinidine</strong></td>
</tr>
<tr>
<td><strong>HMG-CoA reductase inhibitors</strong></td>
</tr>
<tr>
<td><strong>Atorvastatin</strong></td>
</tr>
<tr>
<td><strong>Simvastatin</strong></td>
</tr>
<tr>
<td><strong>Immunosuppressive drugs</strong></td>
</tr>
<tr>
<td><strong>Tacrolimus</strong></td>
</tr>
<tr>
<td><strong>Beta-blockers</strong></td>
</tr>
<tr>
<td><strong>Propranolol</strong></td>
</tr>
<tr>
<td><strong>HIV-protease inhibitors</strong></td>
</tr>
<tr>
<td><strong>Nelfinavir</strong></td>
</tr>
<tr>
<td><strong>Saquinavir</strong></td>
</tr>
<tr>
<td><strong>Theophylline</strong></td>
</tr>
</tbody>
</table>

*HMG-CoA denotes hydroxymethylglutaryl-coenzyme A, and HIV human immunodeficiency virus.
therapy is initiated in a patient who is receiving digoxin or digitoxin, the cardiac glycoside should be measured in serum after it has reached a new steady state to determine whether the dose should be reduced.

**Pharmacodynamic Interactions**

The relatively wide therapeutic index of calcium antagonists makes the clinical importance of all but a few pharmacodynamic interactions quite limited. The following are selected examples of clinically important interactions.

**Cardiac Interactions**

Treatment with verapamil or diltiazem in combination with amiodarone, digoxin, or a beta-blocker inhibits atrioventricular conduction and sinus-node function more than does treatment with verapamil or diltiazem alone. When the combination of a calcium antagonist and digoxin causes advanced heart block, accelerated atrioventricular junctional escape may occur. Although combined oral treatment with a calcium antagonist and a beta-blocker is usually well tolerated, combined intravenous administration of verapamil and a beta-blocker has resulted in asystole and should not be attempted. In patients with impaired left ventricular function, treatment with verapamil or diltiazem in combination with a beta-blocker can lead to additive negative inotropic effects.79

**Vascular Interactions**

Concomitant administration of a calcium antagonist with other antihypertensive drugs causes an increased antihypertensive effect. In many instances this result may be desired; however, when a calcium antagonist is given in combination with a beta-blocker, sinus-node depression may occur, and when it is given with a diuretic, hypovolemia and postural hypotension may occur.80

**Noncardiovascular Interactions**

Concurrent treatment with lithium and verapamil can predispose patients to lithium neurotoxicity.81 Nonvascular peripheral edema has been reported during treatment with all calcium antagonists. Gingival hyperplasia may occur in patients who are given a dihydropyridine, but it is rare in those given verapamil or diltiazem. Constipation occurs as a result of relaxation of gastrointestinal smooth muscle and may be more common with verapamil. Headache, which is common in patients who are treated with rapid-acting calcium antagonists, is less common with slow-acting and sustained-release preparations.

**SPECIAL CONSIDERATIONS**

**Older Patients**

Calcium antagonists are effective for the treatment of hypertension in older patients.82 Intravenous administration of verapamil, diltiazem, or amiodipine results in a greater hypotensive effect in older than in younger patients with hypertension at a given drug concentration.83,85 The clearance of most calcium antagonists is decreased in older patients, as compared with younger patients; this difference results in higher

---

**TABLE 3. REPORTED OR POSSIBLE EFFECTS OF OTHER DRUGS, NUTRIENTS, DISEASE, AND OTHER FACTORS ON CALCIUM ANTAGONISTS.**

<table>
<thead>
<tr>
<th>VARIABLE</th>
<th>CALCIUM ANTAGONIST AFFECTED</th>
<th>MECHANISM</th>
<th>PHARMACOKINETIC EFFECT</th>
<th>POTENTIAL CLINICAL EFFECT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cimetidine</td>
<td>Verapamil</td>
<td>Decreased clearance</td>
<td>Slight increase in exposure to active drug</td>
<td>Prolongation of PR interval</td>
</tr>
<tr>
<td>Dihydropyridines</td>
<td></td>
<td>Decreased clearance</td>
<td>Slight increase in exposure to active drug</td>
<td>Unknown</td>
</tr>
<tr>
<td>Sulfipyrazone</td>
<td>Verapamil</td>
<td>Decreased clearance</td>
<td>Increased exposure to active drug</td>
<td>Prolongation of PR interval</td>
</tr>
<tr>
<td>Rifampin</td>
<td>All types</td>
<td>Increased clearance</td>
<td>Large decrease in exposure to active drug</td>
<td>Decreased calcium-antagonist effect</td>
</tr>
<tr>
<td>Phenytoin or phenobarbital</td>
<td>All types</td>
<td>Increased clearance</td>
<td>Decreased exposure to active drug</td>
<td>Possible decrease in calcium-antagonist effect</td>
</tr>
<tr>
<td>Ketoconazole</td>
<td>All types</td>
<td>Decreased clearance</td>
<td>Increased exposure to active drug</td>
<td>Possible increase in calcium-antagonist effect</td>
</tr>
<tr>
<td>Grapefruit juice</td>
<td>Felodipine, nisoldipine, perhaps other dihydropyridines</td>
<td>Increased bioavailability</td>
<td>Increased exposure to active drug</td>
<td>Possible increase in calcium-antagonist effect</td>
</tr>
<tr>
<td>Liver disease</td>
<td>All types</td>
<td>Increased bioavailability, decreased clearance</td>
<td>Increased exposure to active drug</td>
<td>Increased calcium-antagonist effect</td>
</tr>
<tr>
<td>Advanced age</td>
<td>All types</td>
<td>Decreased clearance</td>
<td>Increased exposure to active drug</td>
<td>Increased hypotensive effect</td>
</tr>
</tbody>
</table>
serum drug concentrations in older patients. This difference may be a factor in the perception that older patients have greater antihypertensive responses to calcium antagonists.

The sinoatrial suppressive effects of verapamil and diltiazem, and the resulting decrease in the heart rate, are also greater in older than in younger patients. In contrast, the delay in atroventricular conduction associated with treatment with verapamil and diltiazem is similar or possibly smaller in older than in younger patients. Calcium antagonists are effective for the treatment of angina in older patients; however, few studies have compared responses in older and younger patients.

With respect to morbidity, nitrendipine, a dihydropyridine that is not available in the United States, was associated with a decrease in the risk of stroke among elderly patients in the Systolic Hypertension in Europe Trial. Nonetheless, the benefit of a thiazide diuretic alone or in combination with a beta-blocker or a potassium-sparing diuretic as a treatment for systolic hypertension is similar to that of a calcium antagonist. It is therefore difficult to recommend a dihydropyridine as first-line therapy for isolated systolic hypertension in elderly patients. The observed association between calcium-antagonist therapy and an increased incidence of myocardial infarction may be of particular concern in older patients.

Patients with Diabetes Mellitus

Calcium antagonists are an option for the treatment of hypertension associated with diabetes mellitus because they do not adversely affect glucose metabolism, lipid metabolism, or renal function. Thiazide diuretics and beta-blockers decreased morbidity and mortality among hypertensive patients in multiple studies, each of which included a substantial number of patients with diabetes. In contrast, with the exception of nitrendipine in one study, calcium antagonists simply lowered blood pressure.

Studies of the effect of calcium antagonists on proteinuria and progression of nephropathy in patients with diabetes were prompted by the finding that angiotensin-converting–enzyme inhibitors may slow the progression of diabetic nephropathy and by the demonstration that, in animals, nondihydropyridine calcium antagonists increase renal blood flow and increase glomerular filtration by blocking pregglomerular vasoconstriction. In relatively small placebo-controlled studies of patients who had hypertension and diabetes, dihydropyridine calcium antagonists did not slow the development of proteinuria or renal failure, but verapamil and diltiazem did. In a small study, nifedipine delayed the increase in proteinuria in normotensive patients with diabetes; however, it did so less effectively than lisinopril.

At present, in view of the greater evidence of a benefit of angiotensin-converting–enzyme inhibitors and beta-blockers in patients who have hypertension and diabetes, the relative paucity of data on calcium antagonists in these patients, and the recent finding that the risk of a vascular event may be increased during calcium-antagonist treatment in such patients, calcium antagonists cannot be considered as first-line therapy for these patients.

Patients with Congestive Heart Failure

All classes of calcium antagonists have dose-dependent negative inotropic effects in vitro and in animals. In vivo, this action is variably counterbalanced by baroreceptor-mediated reflex responses and the reduction in afterload resulting from the decrease in blood pressure. In vivo, nifedipine has fewer negative chronotropic or inotropic effects than verapamil or diltiazem; however, in long-term studies hemodynamic deterioration occurred in some patients with congestive heart failure who were treated with dihydropyridines and these drugs do not have the benefits associated with treatment with an angiotensin-converting–enzyme inhibitor. Because of the potential detrimental effects of calcium antagonists in patients with congestive heart failure and ischemic heart disease, and because only weak data suggest a benefit in patients with nonischemic cardiomyopathy when the calcium antagonist is given in combination with an angiotensin-converting–enzyme inhibitor, calcium antagonists should not be given to patients with congestive heart failure.

Overdose of Calcium Antagonists

Reports of overdoses of all three types of calcium antagonists (verapamil-like, diltiazem-like, and nifedipine-like) have been published, with the greatest number of cases occurring with verapamil. The most common presentation is hypotension and bradycardia, often with second- or third-degree heart block. There are no available agonists; therefore, treatment consists of the removal of the drug from the gastrointestinal tract by gastric lavage and ingestion of activated charcoal and correction of the hypotension and cardiac-conduction abnormalities by the intravenous administration of calcium gluconate or calcium chloride and fluids during electrocardiographic and blood-pressure monitoring. Inotropic and chronotropic drugs may be given as needed. Norepinephrine or amrinone is usually given for inotropic support. Abnormalities in cardiac rhythm and conduction may be more resistant to therapy, and responses to calcium, atropine, or isoproterenol may be insufficient, necessitating temporary transvenous pacing.

CONCLUSIONS

L-type calcium-channel antagonists inhibit the transmembrane flow of calcium, resulting in antagonism of vascular smooth muscle, contraction of myocardial smooth muscle, reduction of blood pres-
sure, and coronary-artery dilation. Calcium antagonists have assumed a major role in the treatment of patients with hypertension or coronary artery disease. Verapamil and diltiazem slow the heart rate and prolong atrioventricular conduction, which can prevent supraventricular arrhythmias in patients without accessory bypass pathways or control the rates of ventricular response in patients with atrial arrhythmias. Because these drugs are metabolized largely by the cytochrome P-450 family of enzymes, drug interactions can occur. The calcium antagonists are highly effective antihypertensive and antiangiinal drugs and have a role in multidrug therapy for these disorders.

Supported by grants from the National Institutes of Health (AG-08226-08 and GM-08386-09, to Dr. Abernethy, and AG-00768-02, to Dr. Schwartz).

We are indebted to Ms. Anne Nguyen and Ms. Julita Niece for preparing the manuscript and to Dr. Nikolai M. Soldatov for providing the original version of Figure 1.

REFERENCES


Millard RW, Grupp G, Grupp IL, DiSalvo J, DePover A, Schwartz A. Chronotropic, inotropic, and vasodilator actions of diltiazem, nifedipine,


